VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development (original) (raw)
- Original Paper
- Published: 28 July 1998
- Rodolfo Murillas1 nAff3,
- Marcela Bolontrade2,
- Claudio J Conti2 &
- …
- José L Jorcano1
Oncogene volume 17, pages 303–311 (1998)Cite this article
- 831 Accesses
- 3 Altmetric
- Metrics details
Abstract
Upregulation of keratinocyte-derived VEGF-A expression has recently been established in non-neoplastic processes of skin such as wound healing, blistering diseases and psoriasis, as well as in skin neoplasia. To further characterize the effects of VEGF-A in skin in vivo, we have developed transgenic mice expressing the mouse VEGF120 under the control of a 2.4 kb 5′ fragment of keratin K6 gene regulatory sequences that confers transgene inducibility upon hyperproliferative stimuli. As expected from the inducible nature of the transgene, two of the three founder mice obtained (V27 and V208), showed no apparent phenotype. However, one founder (V2), mosaic for transgene integration, developed scattered red spots throughout the skin at birth. The transgenic offspring derived from this founder developed a striking phenotype characterized by swelling and erythema, resulting in early postnatal lethality. Histological examination of the skin of these transgenics demonstrated highly increased vascularization and edema leading to disruption of skin architecture. Expression of the transgene was silent in adult animals of lines derived from founders V27 and V208. Phorbol ester-induced hyperplasia resulted in transgene induction and increased cutaneous vascularization in adult transgenic mice of these lines. Skin carcinogenesis experiments performed on hemizygous crosses of V208 mice with activated H-ras-carrying transgenic mice (TG.AC) resulted in accelerated papilloma development and increased tumor burden. Previous results from our laboratory showed that VEGF upregulation is a major angiogenic stimulus in mouse epidermal carcinogenesis. By overexpressing VEGF in the skin of transgenic mice we now move a step further toward showing that VEGF-mediated angiogenesis is a rate-limiting step in the genesis of premalignant lesions, such as mouse skin papilloma. Our transgenic mice constitute an interesting model system for in vivo study of the cutaneous angiogenic process and its relevance in tumorigenesis and other skin diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Author information
Author notes
- Rodolfo Murillas
Present address: Laboratory of Carcinogenesis and Tumor Promotion. National Cancer Institute, National Institutes of Health, Bethesda, 20892, Maryland, USA
Authors and Affiliations
- Department of Cell and Molecular Biology, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, 28040, Spain
Fernando Larcher, Rodolfo Murillas & José L Jorcano - University of Texas M.D. Anderson Cancer Center Science Park, Smithville, 78957, Texas, USA
Marcela Bolontrade & Claudio J Conti
Authors
- Fernando Larcher
You can also search for this author inPubMed Google Scholar - Rodolfo Murillas
You can also search for this author inPubMed Google Scholar - Marcela Bolontrade
You can also search for this author inPubMed Google Scholar - Claudio J Conti
You can also search for this author inPubMed Google Scholar - José L Jorcano
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
Larcher, F., Murillas, R., Bolontrade, M. et al. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development.Oncogene 17, 303–311 (1998). https://doi.org/10.1038/sj.onc.1201928
- Received: 12 August 1997
- Revised: 24 February 1998
- Accepted: 24 February 1998
- Published: 28 July 1998
- Issue Date: 23 July 1998
- DOI: https://doi.org/10.1038/sj.onc.1201928